Galmed Pharmaceuticals Ltd.
GLMD
$0.52
-$0.01-1.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.57% | 65.38% | -20.74% | 52.76% | -17.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.71% | 85.04% | 4.18% | 72.59% | -9.78% |
| Operating Income | -61.71% | -85.04% | -4.18% | -72.59% | 9.78% |
| Income Before Tax | -73.01% | -50.14% | 1.15% | -122.97% | 13.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.01% | -50.14% | 1.15% | -122.97% | 13.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.01% | -50.14% | 1.15% | -122.97% | 13.41% |
| EBIT | -61.71% | -85.04% | -4.18% | -72.59% | 9.78% |
| EBITDA | -- | -83.78% | -3.15% | -81.91% | 10.68% |
| EPS Basic | 53.26% | 59.89% | 84.98% | 61.72% | 70.42% |
| Normalized Basic EPS | 53.26% | 63.69% | 84.98% | 69.79% | 70.42% |
| EPS Diluted | 53.26% | 59.89% | 84.98% | 61.72% | 70.42% |
| Normalized Diluted EPS | 53.26% | 63.69% | 84.98% | 69.79% | 70.42% |
| Average Basic Shares Outstanding | 270.18% | 274.31% | 558.29% | 482.42% | 192.67% |
| Average Diluted Shares Outstanding | 270.18% | 274.31% | 558.29% | 482.42% | 192.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |